enGene Holdings Inc. (NASDAQ:ENGN) Receives $22.38 Average Target Price from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $22.3750.

Several analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of enGene in a research note on Wednesday, December 3rd. Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Tuesday, October 14th. Citigroup restated a “market outperform” rating on shares of enGene in a research note on Wednesday, November 12th. Finally, UBS Group upped their price objective on shares of enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, November 12th.

Institutional Investors Weigh In On enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENGN. Millennium Management LLC raised its stake in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after buying an additional 7,472 shares during the last quarter. MAI Capital Management grew its holdings in enGene by 11.0% during the first quarter. MAI Capital Management now owns 78,067 shares of the company’s stock worth $350,000 after acquiring an additional 7,756 shares during the period. Raymond James Financial Inc. raised its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares in the last quarter. PFS Partners LLC acquired a new position in enGene in the third quarter valued at approximately $61,000. Finally, Cresset Asset Management LLC acquired a new position in enGene in the second quarter valued at approximately $36,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Price Performance

Shares of ENGN opened at $8.17 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The company’s fifty day moving average price is $7.88 and its 200-day moving average price is $5.70. enGene has a 1-year low of $2.65 and a 1-year high of $11.14. The firm has a market capitalization of $527.60 million, a PE ratio of -4.30 and a beta of -0.28.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.